Bioptic

Bioptic Short-term Debt

The Short-Term Debt of Bioptic (6850.TWO) as of Nov 1, 2026 is 6.83 M TWD. In the previous year, Short-Term Debt was 7.41 M TWD — a change of -7.75% (lower).

Short-term Debt

6.83 MTWD

YoY

-7.75%

Last updated:

Short-Term Debt of Bioptic is 2024 6.83 M TWD. Short-Term Debt of Bioptic was 2023 7.41 M TWD. It decreases by -7.75% lower compared to the previous year.

The Bioptic Short-term Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Short-term Debt
Date
Short-term Debt
Jan 1, 2020
4.16 M TWD
Jan 1, 2021
3.99 M TWD
Jan 1, 2022
6.67 M TWD
Jan 1, 2023
7.41 M TWD
Jan 1, 2024
6.83 M TWD
The Bioptic Short-term Debt history
YEARShort-term DebtYoY
6.83 MTWD-7.75%
7.41 MTWD+11.03%
6.67 MTWD+67.17%
3.99 MTWD-3.99%
4.16 MTWD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Bioptic Stock analysis

What does Bioptic do? BiOptic Inc generates revenue through the sale of capillary electrophoresis instruments, including the Qsep100, Qsep1, and Qsep400 series, which are used for biomolecule separation and detection. The company also sells related consumables such as S1, S2, S3, F3 cassettes for DNA fragment analysis, R1 and NR1 cassettes for RNA detection, P2 cassettes for protein analysis, and Q series for quantitative detection. Additionally, BiOptic Inc offers reagents including polymerase chain reaction reagents, veterinary medicine-related reagents, human gene detection reagents, and food-related reagents. These products are primarily sold to customers in China, Hong Kong, and Taiwan, with the company focusing on the healthcare and research sectors. The firm's main customer segments include laboratories, hospitals, and research institutions that require advanced detection equipment and consumables for genetic and molecular analysis. BiOptic Inc's product portfolio targets both human and veterinary medical applications, as well as food safety testing, indicating a diversified market approach. The company's focus on high-precision instruments and specialized reagents positions it to serve clients needing reliable solutions for nucleic acid and protein analysis. BiOptic Inc's revenue streams are derived from direct sales of its instruments, cassettes, and reagents to end-users in the healthcare and research sectors. The company's products are designed for specific applications, such as DNA, RNA, and protein detection, which drives demand from specialized laboratories and medical facilities. By offering a comprehensive range of products, BiOptic Inc ensures that its customers can access all necessary tools for their molecular analysis needs within a single supplier. Bioptic is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Bioptic stock

Short-Term Debt of Bioptic is 6.83 M TWD in 2024.

Short-Term Debt of Bioptic changed from 7.41 M TWD to 6.83 M TWD, representing a -7.75% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Short-Term Debt Bioptic since 2006 – with annual values, charts, and detailed analysis.

Short-term debt represents borrowings due within one year. High short-term debt relative to cash can signal liquidity risk.

Short-Term Debt's TWD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Short-Term Debt's Bioptic historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Bioptic

All Key Metrics — Bioptic